With great interest we read the early electronic publication of the interim results from “Midterm Clinical and Angiographic Follow Up for the First FDA-approved Prospective, Single-arm Trial of Primary Stenting for Stroke: SARIS (Stent-Assisted Recanalization for acute Ischemic Stroke)” by Levy et al.1 The authors used the Wingspan stent (Stryker, former Boston Scientific, Freemont, California), a self-expandable stent used as a first-line therapeutic modality to recanalize an occluded cerebral artery. In our experience2 with a smaller cohort of 7 patients, the Enterprise stent (Cordis, Miami Lakes, Florida), a closed-cell design, partially retrievable stent was used as a rescue therapy where other techniques failed (intravenous tissue plasminogen activator, IV tissue plasminogen activator, Penumbra aspiration system, balloon angioplasty). Obtaining Thrombolysis in Myocardial Infarction (TIMI) 2 and 3 in all the patients. The stent was retrieved in 5 patients and permanently implanted in 2. The median modified Rankin scale was 3 at 1 month and the median National Institutes of Health Stroke Scale improved from 16 to 11 at 24 hours. We obtained TIMI 2 in 3 patients and TIMI 3 in 4 patients. Our results are similar to others, Castano et al3 and Roth et al4 using a different self-expandable stent (Solitaire AB, EV3 Plymouth, Minnesota) and also retrieved after the vessel was recanalized obtaining TIMI 2 and 3 in 90% in both series. Regarding the inclusion criteria, Levy's study limits this technique to a clot burden of <14 mm; this is a disadvantage of using an open-celled stent. With a retrievable device, it can be partially deployed, retrieved, and then deployed on a more proximal or distal location based on the specific need. The theoretical advantage of using the Wingspan stent because of its higher radial force did not seem to offer a clinical advantage since the recanalization rates were similar to ours and previously published with the Solitaire stent.3,4 Temporary stent deployment does not have to carry the risk of developing intrastent stenosis that has been reported as high as 50% additionally prevents the requirement of using long-term antiplatelet agents. We commend the authors for pursuing a prospective Food and Drug Administration study addressing the use of self-expandable stent on cerebral revascularization and presenting angiographic follow-up of the target vessel, which is unique because no other revascularization paper has it. Finally, we agree that prospective randomized trials are required to determine the real value of this new therapeutic modality. Disclosure The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.